{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:54:41Z","timestamp":1790916881747,"version":"4.1.0"},"posted":{"date-parts":[[2026,9,28]]},"group-title":"Bioengineering","reference-count":49,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"name":"National Institutes of Health","award":["R01-HL157189"],"award-info":[{"award-number":["R01-HL157189"]}]},{"name":"National Institutes of Health","award":["R01-NS131279"],"award-info":[{"award-number":["R01-NS131279"]}]},{"name":"National Institutes of Health","award":["R01-HL153510"],"award-info":[{"award-number":["R01-HL153510"]}]},{"name":"National Institutes of Health","award":["R01-HL160694"],"award-info":[{"award-number":["R01-HL160694"]}]},{"name":"National Institutes of Health","award":["R01-HL164594"],"award-info":[{"award-number":["R01-HL164594"]}]},{"name":"National Institutes of Health","award":["UL1TR001878"],"award-info":[{"award-number":["UL1TR001878"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Nanoparticle albumin-bound paclitaxel (Abraxane) was among the first clinically approved nanomedicines and is a first-line chemotherapeutic. It enhances therapeutic efficacy and reduces side effects of paclitaxel. Despite its extensive clinical use, mechanisms of Abraxane\u2019s therapeutic effects are the subject of ongoing study. This work posits a new mechanism for Abraxane\u2019s effects in lung cancers and metastasis. Tracing the albumin component of Abraxane with radioisotopes or fluorophores, we find that Abraxane homes to the lungs. Abraxane\u2019s lung tropism is elevated by inflammation and is eliminated in complement protein C3 knockout mice, showing that complement pathway drives the uptake. Flow cytometry and histology show that neutrophils are the dominant cell type taking up Abraxane in the lungs. We demonstrate Abraxane\u2019s tropism to pulmonary neutrophils in mice and in human donor lungs. We note previously undocumented side effects associated with Abraxane\u2019s lung tropism, including pro-thrombotic and pro-inflammatory responses in acute lung inflammation. We show that Abraxane\u2019s efficacy against lung metastases is affected when lung uptake is eliminated by C3 knockout. Our results provide insight into why Abraxane is effective in lung cancer and metastases. These findings may be used to improve outcomes in patients receiving Abraxane and help design next-generation cancer nanomedicines.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Teaser<\/jats:title>\n                  <jats:p>Nanoparticle albumin-bound paclitaxel, widely used for treatment of non-small cell lung cancer and metastases arising from breast and pancreatic cancer, was found to target neutrophils in the lungs.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.09.27.754839","type":"posted-content","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:10:30Z","timestamp":1790629830000},"source":"Crossref","is-referenced-by-count":0,"title":["Nanoparticle Albumin-Bound Paclitaxel Targets Pulmonary Neutrophils"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0712-2643","authenticated-orcid":false,"given":"Aparajeeta","family":"Majumder","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soomin","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco E.","family":"Zamora","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Marzolini","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Nong","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Brysgel","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyal","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Zaleski","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin T.","family":"Stabler","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam S.","family":"Chase","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Morrisey","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir R.","family":"Muzykantov","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Brenner","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Marcos-Contreras","sequence":"additional","affiliation":[{"name":"Temple University School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob W.","family":"Myerson","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026100121251727000_2026.09.27.754839v1.1","doi-asserted-by":"crossref","unstructured":"S. Hou et al., Application Perspectives of Nanomedicine in Cancer Treatment. Front Pharmacol 13, 909526 (2022).","DOI":"10.3389\/fphar.2022.909526"},{"key":"2026100121251727000_2026.09.27.754839v1.2","doi-asserted-by":"crossref","unstructured":"P. Ma , R. J. Mumper , Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol 4, 1000164 (2013).","DOI":"10.4172\/2157-7439.1000164"},{"key":"2026100121251727000_2026.09.27.754839v1.3","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S88023"},{"key":"2026100121251727000_2026.09.27.754839v1.4","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s3061"},{"key":"2026100121251727000_2026.09.27.754839v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl104"},{"key":"2026100121251727000_2026.09.27.754839v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"2026100121251727000_2026.09.27.754839v1.7","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1366002"},{"key":"2026100121251727000_2026.09.27.754839v1.8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/23808993.2020.1730694","article-title":"Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions","volume":"5","year":"2020","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"2026100121251727000_2026.09.27.754839v1.9","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.8.1041"},{"key":"2026100121251727000_2026.09.27.754839v1.10","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9339-4"},{"key":"2026100121251727000_2026.09.27.754839v1.11","unstructured":"N. Desai , in Albumin in Medicine: Pathological and Clinical Applications, M. Otagiri , V. T. G. Chuang , Eds. (Springer Singapore, Singapore, 2016), pp. 101\u2013119."},{"key":"2026100121251727000_2026.09.27.754839v1.12","doi-asserted-by":"crossref","first-page":"11847","DOI":"10.2147\/IJN.S490400","article-title":"Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database","volume":"19","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"2026100121251727000_2026.09.27.754839v1.13","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.304"},{"key":"2026100121251727000_2026.09.27.754839v1.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2291"},{"key":"2026100121251727000_2026.09.27.754839v1.15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/bjc.2016.215","article-title":"Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer","volume":"115","year":"2016","journal-title":"Br J Cancer"},{"key":"2026100121251727000_2026.09.27.754839v1.16","doi-asserted-by":"crossref","first-page":"11765","DOI":"10.1021\/jacs.9b04272","article-title":"Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin","volume":"141","year":"2019","journal-title":"Journal of the American Chemical Society"},{"key":"2026100121251727000_2026.09.27.754839v1.17","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41565-021-00897-1","article-title":"Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer","volume":"16","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"2026100121251727000_2026.09.27.754839v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-00997-y"},{"key":"2026100121251727000_2026.09.27.754839v1.19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nnano.2014.17","article-title":"Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils","volume":"9","year":"2014","journal-title":"Nat Nanotechnol"},{"key":"2026100121251727000_2026.09.27.754839v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.05.026"},{"key":"2026100121251727000_2026.09.27.754839v1.21","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c01171"},{"key":"2026100121251727000_2026.09.27.754839v1.22","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.0c00366"},{"key":"2026100121251727000_2026.09.27.754839v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.08.030"},{"key":"2026100121251727000_2026.09.27.754839v1.24","doi-asserted-by":"crossref","unstructured":"M. Yan et al., Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications. Frontiers in Cell and Developmental Biology Volume 10 - 2022, (2022).","DOI":"10.3389\/fcell.2022.938289"},{"key":"2026100121251727000_2026.09.27.754839v1.25","doi-asserted-by":"crossref","unstructured":"J. Zhang et al., Engineering and Targeting Neutrophils for Cancer Therapy. Advanced Materials 36, 2310318 (2024).","DOI":"10.1002\/adma.202310318"},{"key":"2026100121251727000_2026.09.27.754839v1.26","doi-asserted-by":"crossref","first-page":"e1804191","DOI":"10.1002\/smll.201804191","article-title":"Neoadjuvant Chemotherapy Based on Abraxane\/Human Neutrophils Cytopharmaceuticals with Radiotherapy for Gastric Cancer","volume":"15","year":"2019","journal-title":"Small"},{"key":"2026100121251727000_2026.09.27.754839v1.27","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nnano.2017.54","article-title":"Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence","volume":"12","year":"2017","journal-title":"Nature Nanotechnology"},{"key":"2026100121251727000_2026.09.27.754839v1.28","doi-asserted-by":"crossref","unstructured":"J. Park et al., A Comparative In Vivo Study of Albumin-Coated Paclitaxel Nanocrystals and Abraxane. Small 14, 1703670 (2018).","DOI":"10.1002\/smll.201703670"},{"key":"2026100121251727000_2026.09.27.754839v1.29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53072"},{"key":"2026100121251727000_2026.09.27.754839v1.30","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c06286"},{"key":"2026100121251727000_2026.09.27.754839v1.31","doi-asserted-by":"crossref","first-page":"2409945","DOI":"10.1002\/adma.202409945","article-title":"Conjugation Chemistry Markedly Impacts Toxicity and Biodistribution of Targeted Nanoparticles, Mediated by Complement Activation","volume":"37","year":"2025","journal-title":"Advanced Materials"},{"key":"2026100121251727000_2026.09.27.754839v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.12.027"},{"key":"2026100121251727000_2026.09.27.754839v1.33","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/s41565-025-01974-5","article-title":"Limiting endosomal damage sensing reduces inflammation triggered by lipid nanoparticle endosomal escape","volume":"20","year":"2025","journal-title":"Nature Nanotechnology"},{"key":"2026100121251727000_2026.09.27.754839v1.34","first-page":"981","article-title":"Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation","volume":"141","year":"1992","journal-title":"Am J Pathol"},{"key":"2026100121251727000_2026.09.27.754839v1.35","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.4874"},{"key":"2026100121251727000_2026.09.27.754839v1.36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jconrel.2022.08.023","article-title":"pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma","volume":"350","year":"2022","journal-title":"J Control Release"},{"key":"2026100121251727000_2026.09.27.754839v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.12.013"},{"key":"2026100121251727000_2026.09.27.754839v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.06.013"},{"key":"2026100121251727000_2026.09.27.754839v1.39","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.nano.2016.12.019","article-title":"Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions","volume":"13","year":"2017","journal-title":"Nanomedicine: Nanotechnology, Biology and Medicine"},{"key":"2026100121251727000_2026.09.27.754839v1.40","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2010.00138"},{"key":"2026100121251727000_2026.09.27.754839v1.41","doi-asserted-by":"crossref","unstructured":"Z. Wang , J. S. Brenner , The Nano-War Against Complement Proteins. Aaps j 23, 105 (2021).","DOI":"10.1208\/s12248-021-00630-9"},{"key":"2026100121251727000_2026.09.27.754839v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.04.027"},{"key":"2026100121251727000_2026.09.27.754839v1.43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102914"},{"key":"2026100121251727000_2026.09.27.754839v1.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01522.x"},{"key":"2026100121251727000_2026.09.27.754839v1.45","doi-asserted-by":"crossref","unstructured":"S. Vandendriessche , S. Cambier , P. Proost , P. E. Marques , Complement Receptors and Their Role in Leukocyte Recruitment and Phagocytosis. Frontiers in Cell and Developmental Biology Volume 9 - 2021, (2021).","DOI":"10.3389\/fcell.2021.624025"},{"key":"2026100121251727000_2026.09.27.754839v1.46","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-017-2727-4"},{"key":"2026100121251727000_2026.09.27.754839v1.47","doi-asserted-by":"crossref","unstructured":"G. Roviello et al., Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Sci Rep 10, 19281 (2020).","DOI":"10.1038\/s41598-020-76465-9"},{"key":"2026100121251727000_2026.09.27.754839v1.48","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1200\/JCO.23.01965","article-title":"Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia","volume":"43","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"2026100121251727000_2026.09.27.754839v1.49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41572-025-00642-1","article-title":"Lung metastases.","volume":"11","year":"2025","journal-title":"Nature Reviews Disease Primers"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.27.754839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:25:28Z","timestamp":1790915128000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.27.754839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":49,"URL":"https:\/\/doi.org\/10.64898\/2026.09.27.754839","relation":{},"subject":[],"published":{"date-parts":[[2026,9,28]]},"subtype":"preprint"}}